LUCD
Lucid Diagnostics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Consensus Rating "Strong Buy"
MACD Golden Cross
Ample Liquidity
Negative Gross Margin
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LUCD
Lucid Diagnostics Inc.
A provider of non-invasive diagnostic tests for esophageal cancer and gastrointestinal diseases
360 Madison Avenue , 25th Floor , New York, NY 10017
--
Lucid Diagnostics Inc., was incorporated in Delaware on May 8, 2018. The company is a commercial-stage medical diagnostic technology company focusing on millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simple reflux, which is at risk of developing esophageal precancerous lesions and cancers, especially highly lethal esophageal adenocarcinoma (EAC). The company believes that the lead product, the ESOGuard esophageal DNA test on samples collected using the ESOCheck esophageal cell collection device in a short, non-invasive office procedure, constitutes the first and only commercially available diagnostic test that can be used as a broad screening tool to prevent EAC death by early detection of esophageal precancerous lesions and cancer in at-risk GERD patients. The company believes that the impact of ESoGuard in preventing EAC deaths may be as great as the impact of extensive Pap test screening in preventing cervical cancer deaths.
Earnings Call
Q2/2025
Estimate EPS-0.1
Actual EPS-0.1
Estimate Revenue1.15M
Actual Revenue1.16M
PAVmed's Q2 2025 Earnings Call: Unraveling Contradictions in Medicare Strategy, FDA Timelines, and Biopharma Expansion
Aug 13,2025 05:30
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.09
Actual EPS-0.1
Estimate Revenue1.35M
Actual Revenue1.21M
Lucid Diagnostics' Q3 2025: Contradictions in Medicare Coverage Timelines, Patient Engagement, and Commercial Strategies
Nov 12,2025 03:08
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
LUCD has released its 2025 Q3 earnings. EPS was reported at -0.1, versus the expected -0.09, missing expectations. The chart below visualizes how LUCD has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
LUCD has released its 2025 Q3 earnings report, with revenue of 1.21M, reflecting a YoY change of 3.33%, and net profit of -10.40M, showing a YoY change of 15.96%. The Sankey diagram below clearly presents LUCD's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
